Shunned by Commercial Markets, Biotechs can Turn to Government Funds

Image: Anne MacNamara Researchers disheartened by the slowdown in private money for genomics projects should keep an eye on the Congressional budget, under debate now. US Government agencies are stepping up their spending on the search for genomic keys to disease. "It's a great time for genomics, as far as we're concerned," says Maria Giovanni, assistant director for microbial genomics and related technology development for the National Institute of Allergy and Infectious Diseases (NIAID). NI

Written byPeg Brickley
| 4 min read

Register for free to listen to this article
Listen with Speechify
0:00
4:00
Share

Researchers disheartened by the slowdown in private money for genomics projects should keep an eye on the Congressional budget, under debate now. US Government agencies are stepping up their spending on the search for genomic keys to disease. "It's a great time for genomics, as far as we're concerned," says Maria Giovanni, assistant director for microbial genomics and related technology development for the National Institute of Allergy and Infectious Diseases (NIAID).

NIAID is asking Congress to fund $103.6 million (US) in microbial genome sequencing projects in 2003, more than double the $47.2 million in the current year's budget. The generous government requests follow a withdrawal of venture capital investment. Four deals for genomics companies in 2002 amounted to only $26 million, a 76% decline from the $110 million raised by 10 companies in 2001.

FAME AND FORTUNE The popularity of genomics research accounts for the disparity between public and private ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies